Celltrion
http://
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celltrion
Celltrion’s Subcutaneous Infliximab Lands On Big PBM Formulary List
One down, two more to go. Celltrion seals a formulary deal with one of the top three PBMs in the US for its subcutaneous infliximab product Zymfentra.
Celltrion Eyes Near-Term Omalizumab Opportunity With CHMP Backing
The pool of prospective Xolair biosimilars is small, with only Teva and Kashiv BioSciences/Alvotech disclosing Phase III comparison trials for their biosimilar products. Ahead of them in the pack, Celltrion has just taken a giant stride towards the first pan-European marketing approval.
Aurobindo One Step Closer To Xolair Biosimilar Registration
With originator Xolair’s patents already expired or about to end next year, Aurobindo’s CuraTeQ is on track with its omalizumab biosimilar for regulatory filings in 2024/2025, following a Phase I trial completion.
Celltrion Takes Aim At US Infliximab Market With Subcutaneous Launch
Celltrion has delivered on its long-awaited US launch of its Zymfentra subcutaneous formulation of infliximab, sold in other territories as Remsima SC.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice